Impact Factor
3.26
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.95
2,029 total citations
h5-index
56
h5 depth signal
Cited share
36.5%
396 of 1,084
Total citations
2,029
Citation footprint
Metric signal
1.97
External metric anchor
Self-citation
1.3%
27 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,801
China
437
United Kingdom
379
Japan
271
Germany
226
Citing Fields of Research
Oncology
1,817
Cancer, Autophagy & Apoptosis
1,121
Cancer & Development
1,091
Immunology
949
Breast Cancer
639
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
11,971
Articles tracked across the journal lifetime
Indexed publication set
1,084
396 cited publications
Last 12 months
615
51.3 publications/month
Open access share
10.9%
67 OA publications in the last year
Leading citing country
United States
2,801 citing publications
Leading citing field
Oncology
1,817 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Nov. 2001-
v1n1,Nov. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Immunology
Cancer, Autophagy & Apoptosis
Cancer & Development
Immunotherapy
Lung Cancer
Breast Cancer
Issuing & Sponsoring Bodies
Contributor
American Association for Cancer Research
Broad Categories
Antineoplastic Agents
Cancer, Autophagy & Apoptosis
Immunotherapy
DNA Damage
Immunology
Lung Cancer
Cancer & Development
MeSH Descriptors
Anticarcinogenic Agents
Antineoplastic Agents
Genetic Therapy
Neoplasms
Pharmacogenetics
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/1535-7163.mct-26-0483
Open DOI
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during thera...
02
DOI 10.1158/1535-7163.mct-26-0270
Open DOI
Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma
High-risk neuroblastoma (NB) is an aggressive pediatric malignancy characterized by a high proliferative capacity, intrinsic replication stress, and poor clinical outcomes. Although mitotic inhibitors show preclinical efficacy, their cli...
03
DOI 10.1158/1535-7163.mct-25-1231
Open DOI
Targeting Pancreatic Cancer with Adenoviral Vectors Equipped with Transgenes
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and current therapeutics provide limited benefits to patients. Desmoplasia and the highly immunosuppressive tumor microenvironment (TME) play a significant role i...
04
DOI 10.1158/1535-7163.mct-25-1491
Open DOI
Targeting YAP/TEAD signaling disturbs RNA Pol II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer
Gastroesophageal adenocarcinoma (GEAC) is a significant global cancer burden. Our previous studies demonstrated that YAP/TEAD are highly expressed in GEAC, and play a critical role in tumor progression, therapy resistance, and metastasis...
05
DOI 10.1158/1535-7163.mct-26-0239
Open DOI
PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors
Hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer that progresses on CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) faces a major therapeutic challenge, and chemotherapy is frequently used despite its modest ...
06
DOI 10.1158/1535-7163.mct-26-0200
Open DOI
Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids
RAS genes are among the most frequently altered oncogenes in cancer. Recently developed agents selectively target specific RAS variants or broadly inhibit multiple RAS alterations, including oncogenic variants and amplifications. Four RA...
07
DOI 10.1158/1535-7163.mct-25-1441
Open DOI
GNTbm-38, a Novel Epigenetic Modulator, Performs Immune Activation and Reprogramming of the Tumor Microenvironment
The efficacy of immunotherapy depends on the composition of immune cells, including cytotoxic T cells (CTLs), etc., in the tumor microenvironment (TME). However, a significant proportion of patients with pre-existing immunity fail to res...
08
DOI 10.1158/1535-7163.mct-25-1241
Open DOI
Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate Against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein with elevated expression in primary and metastatic prostate cancer (PCa) compared with normal prostate tissues; with low levels in renal proximal tubules, ...
09
DOI 10.1158/1535-7163.mct-26-0020
Open DOI
Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia
The GAS6/AXL pathway plays a crucial role in promoting tumor survival and therapy resistance in various cancers. However, its significance in acute lymphoblastic leukemia (ALL) and the potential for its therapeutic targeting remain incom...
10
DOI 10.1158/1535-7163.mct-26-0454
Open DOI
Structural Basis and Preclinical Efficacy of MG1124, a Novel CEACAM1-Targeting Antibody Synergizing with PD-1 Blockade
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) homodimerization mediates tumor immune evasion, presenting a compelling target to overcome resistance to PD-1 blockade. However, defining a precise structural and pharma...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 19, no. 12 (Dec. 2020).
Also issued online.